Async reviewMen and women

Tesamorelin

A growth-hormone-releasing peptide targeted at visceral fat and body composition. Prescribed after a metabolic and IGF-1 panel; reviewed asynchronously.

TherapyCompounded tesamorelin, nightly subcutaneous injection, dosed per your provider after labs

ScheduleNightly

$249/ month

Medication + provider care + monitoring

Billed $249 monthly. Cancel any time.

Prescription required. Subject to provider evaluation.

Start treatment · check eligibility

Auto-renews each cycle. Cancel any time before your next shipment. If your provider doesn't prescribe, the plan portion is refunded automatically; you pay only for labs.

What's included

Provider review of labs and history
Compounded tesamorelin and injection supplies
Free monthly shipping, cold-chain packaging
Unlimited care-team messaging
Dose adjustments on IGF-1 and response
Follow-up labs at 12 weeks, then every 6 months
Initial lab panel billed separately ($89 est.)

1 statesProviders licensed in each

100%Prescriptions preceded by labs

Named MDYou see who prescribes before you pay

$0Plan cost if you're not prescribed

Is this medication for you?

Your provider makes the final call after labs. This is where most patients start.

Check eligibility · 3 min

Often a fit

Adults with stubborn abdominal or visceral fat despite training
Normal or low IGF-1 for age
Normal A1c and fasting insulin, or willing to address them first

Not prescribed if

Active cancer or history of pituitary tumor
Pregnant or breastfeeding
Uncontrolled diabetes (A1c out of range)

Your first 90 days

Day 0Eligibility, intake, payment

Day 2–7Lab panel: CBC, A1c, fasting insulin, IGF-1

Day 7–9Async provider review; questions by message

Day 9–14First shipment arrives

Week 12Repeat labs, dose adjusted

What to expect

01Waist and visceral fat changes build over 3–6 months of nightly use.

02IGF-1 is rechecked at 12 weeks; dose is adjusted to keep it in range.

03Glucose and insulin are watched closely, since GH-axis peptides can raise them.

Who prescribes

A licensed provider reviews your labs and history and decides whether this treatment is right for you. Every prescription is written by a named provider, never a questionnaire.

Built on your labs

Illustrative panelbaseline · 12 wk

IGF-1

A1c

Fasting insulin

CBC

CBC, A1c, fasting insulin and IGF-1 at baseline and 12 weeks, then every 6 months. Dose is set on IGF-1 response and glucose markers.

Safety information

This is a compounded medication prescribed patient-specifically when your provider documents a clinical reason. Compounded medications are not FDA-approved and are not a version of, or equivalent to, any FDA-approved medication. Not for people with active cancer, pituitary disease, or who are pregnant. Common effects: injection-site reactions, joint aches, fluid retention, and a rise in blood glucose; your provider monitors A1c and fasting insulin.

This is a compounded medication. Compounded medications are not FDA-approved and are not a version of, or equivalent to, any FDA-approved medication. They are prescribed patient-specifically only when your provider documents a clinical reason for a compounded formulation.